14-CpG-Based Signature Improves the Prognosis Prediction of Hepatocellular Carcinoma Patients

<div>Validation of the 14-CpG-based signature among HCC patients in the validation cohort (<i>N</i> = 108). (a) The heat map of the methylation levels of the 14 CpGs in high-risk and low-risk patients; (b) distribution of overall status of high-risk and low-risk patients; (c) Kaplan–Meier analysis of overall survival time of high-risk and low-risk patients.</div>

BioMed Research International

fig4

Figure 4

Figure 4: 14-CpG-Based Signature Improves the Prognosis Prediction of Hepatocellular Carcinoma Patients 